Add news
March 2010April 2010May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020January 2021February 2021March 2021April 2021May 2021June 2021July 2021August 2021September 2021October 2021November 2021December 2021January 2022February 2022March 2022April 2022May 2022June 2022July 2022August 2022September 2022October 2022November 2022December 2022January 2023February 2023
News Every Day |

US risks falling behind foreign competitors on next generation vaccines. Congress must act now

US risks falling behind foreign competitors on next generation vaccines. Congress must act now

As the United States heads into its third pandemic winter, White House COVID Coordinator Ashish Jha says regarding tools: "the medicine cabinet has actually shrunk." While the rapid development of mRNA vaccines in 2020 and rollout in 2021 put the United States firmly on the map as the global leader in COVID-19 pharmaceutical innovation and global vaccine provision, this has not kept pace with continued vaccine innovation. While technology developed and proven here in the us is now used in 112 countries worldwide, there is now a risk this lead is being lost. In order not to squander that lead and the geopolitical advantages it confers, the United States needs to keep innovating. Congress must act now to fund the development of next generation vaccines.  

Today, as the virus mutates to evade the protection once almost assured by hallmark mRNA vaccines and treatments, the race to develop next generation vaccines—and the downstream impacts of that technology—is quietly underway. Technologies such as mucosal entry, inhaled vaccines, or variant-proof pan-coronavirus vaccines hold promise for blocking transmission and getting ahead of continuously mutating variants. But despite decades of basic research funding, the U.S. risks falling behind foreign competitors in bringing these new technologies to market.  

Take, for example, the case of the nasal vaccine developed by scientists at the Washington University in St. Louis. Based on early promising studies, Indian vaccine maker Bharat Biotech licensed Washington University’s nasal vaccine technology in 2020, started clinical trials in India in March of 2021, and completed its phase 3 trial in August of 2022, thus allowing to India to take the global-lead to approve the vaccine this September. In October 2022, the same Washington University’s adenovirus-vector-based mucosal vaccine technology was licensed by Pennsylvania-based Ocugen—however, to make the technology available in the United States, clinical trials in the U.S. are critically needed. The United States risks, as the New York Times put it, “creating a scenario in which Americans would have to travel abroad for the latest in American vaccine technology” if the status quo persists. 

Meanwhile, China aims to leapfrog ahead and recently began to roll out a Chinese-developed inhaled mucosal vaccine to its population based on similar technology on a large scale. While no head-to-head comparisons with Pfizer and Moderna vaccines have been done, China is already nearing completion of a large Phase 3 trial and has begun a Phase 4 trial to evaluate post-market clinical impact of its inhaled vaccine—in other words, China may be pulling ahead. In contrast, while the U.S. has the WU mucosal vaccine ready to test in the U.S. and able to enter human trials quickly—no trials are ready due to complete absence of new congressionally-approved funding.  

A U.S. trial studying the effectiveness of a mucosal vaccine’s ability to induce protective immunity at the point of entry of the virus, thus reducing infection and transmission, needs to be urgently conducted—but this is lacking in critical support. A series of new research articles undergirding the potential superiority of inhaled vaccine, here and here, showed that an aerosolized (inhaled) vaccine delivered via a nebulized form not only produced a greater antibody response than the intramuscular version, but also raised antibody levels over 9-fold, and did so at a much lower dose – important for lowering potential side events. More importantly, as Akiko Iwasaki and Eric Topol wrote in Science, inhaled vaccines also have the potential to induce a broader ‘mucosal immunity’, which could better defend against breakthrough infection, not just severe disease. This is why we need a mucosal vaccine trial funded soon. 

Basic research across a range of new technologies remains strong in the U.S., but the push to commercialize these innovations is lagging. In October, researchers funded in part by US taxpayer dollars through NIH and led by Professor Iwasaki at Yale published results of a new approach to mucosal immunity called ‘prime and spike’ in Science that shows promise in reducing transmission.  NIH-funded researchers in Texas are also part of a broader research push to develop variant-proof vaccines with encouraging results in animal models published in Science in September. 

“The United States and democratic nations have an inherent advantage – a robust clinical trial process with transparency that can garner global credibility that autocratic nations like China and Russia could only dream of,” says Lindsay Gorman, head of Technology and Geopolitics at the Alliance for Securing Democracy at the German Marshall Fund and a former White House advisor, “But only if we play the cards we have by aggressively running trials and rapidly producing public results – like we did with the first generation of vaccines in 2020.  

“The US and China have both identified biotechnology as a strategic priority area for national competitiveness,” she says. Yet the next generation of mucosal-administered COVID vaccines have stalled in the United States.  By putting all our eggs solely into the basket of first-generation COVID vaccines, the U.S. risks falling behind foreign rivals eager to lead in Gen 2.0. There’s still opportunity for the United States to come out with the 2.0 global winner. But in the face of foreign competition, it will require investing in, expediting, and rigorously testing next generation technologies. 

As Congress takes up funding proposals in the lame-duck session and early next year, the White House has requested $5 billion for new vaccines and treatments. Funding that is specifically earmarked for next generation vaccine development is an urgent priority both for the moment and for long-term US biotechnology competitiveness. Such funds should go to BARDA, but also DARPA, which was instrumental to the development of mRNA technology as well as monoclonal antibody treatments. In this next generation ‘biotech space race,’ the urgency of now to not lose our lead or let China leapfrog the U.S. in vaccine technology for COVID, flu, and future pandemic viruses is critical.  

Absent dedicated congressional funding, and funding deployed very soon, the next generation of COVID vaccines to hopefully end the pandemic once and for all, may instead come from overseas and controlled by overseas countries and corporations – even if based on U.S.-origin technology. Therefore, the U.S. risks, as the New York Times put it, “creating a scenario in which Americans would have to travel abroad for the latest in American vaccine technology” if the current funding lag continues. 

We cannot rest on our early achievements of a successful first-generation mRNA vaccines, that have been hailed in the first two years of the pandemic as a triumph of decades of US innovation, yet, only to see our gains slip away in year three of the pandemic as variants evade our ability to curb their spread, and thus, more resistant variants. We are only at halftime of the pandemic—let's not blow our biotech lead by resting on our laurels. 

Eric Feigl-Ding is an epidemiologist and health economist, and the Chief of the COVID Task Force at the World Health Network, and faculty at the New England Complex Systems Institute. 


Александр Вдовин: в чем преимущества хирургического фейслифтинга

AMSTERDAM Walking tour and city highlights in 4K

The Ultimate SAUDI ARABIAN FOOD Tour in Riyadh! 5 Best Restaurants You Can't Miss!

AUSTRIAN AIRLINES Boeing 777 Business Class Vienna to Mauritius trip report (4K)

The Bermuda Triangle Explained

Read also

A lifetime subscription to TransferCloud is on sale for under £60

Waste crime: how online advertising platforms are facilitating illegal dumping

EastEnders spoilers: Ryan Malloy’s comeback storyline revealed with a massive betrayal

News, articles, comments, with a minute-by-minute update, now on

News Every Day

AUSTRIAN AIRLINES Boeing 777 Business Class Vienna to Mauritius trip report (4K) — latest news 24/7. You can add your news instantly now — here

News Every Day

AUSTRIAN AIRLINES Boeing 777 Business Class Vienna to Mauritius trip report (4K)

Sports today

Новости тенниса

Первая ракетка Казахстана совершил падение в рейтинге ATP

Спорт в России и мире

Сколько игроков в баскетбольной команде?

All sports news today

Sports in Russia today


Сколько игроков в баскетбольной команде?

Новости России

Game News

Evil Dead: The Game gets a new 'Splatter Royale' mode

Українські новини

Замість дитячого садочку з’явилась житлова будівля

Губернаторы России

Когда ждать весеннее тепло в Москве в 2023 году: прогноз эксперта Поздняковой

МегаФон запустил решение для организации корпоративной телефонии

Генконсульство Турции сохранит мемориал с цветами в Петербурге и откроет книгу соболезнований

В резонансном убийстве четы московских пенсионеров обвинили их сына

В аэропорту Васьково готовятся принимать региональные авиарейсы

Юрий Башмет: Я, конечно, не Гагарин, но тоже был первым

Аранжировка Песен. Аранжировка Музыки. Создание Аранжировок.

Башмет рассказал о дружбе с Михалковым

Открытие выставки прошло в мемориальном музее Булата Окуджавы

Тимофей Скатов рассказал, что придало ему уверенности в матче Кубка Дэвиса против Гарина

Андрей Голубев посетил Каширский Центр сбора гуманитарной помощи

Надя Подорошка стала чемпионкой турнира WTA 125 в Колумбии

18-летний Артур Фис прокомментировал первую победу на турнирах ATP

Когда ждать весеннее тепло в Москве в 2023 году: прогноз эксперта Поздняковой

Шапки мужские и женские (акция от Wildberries / Y're на головные уборы)

США собираются пустить «под нож» Евросоюз — эксперт

В нижегородском монастыре нашли старинную икону «Крест-Мощевик с предстоящими»

Хоккей в Клину

Профессор Абдалла: заявление Путина подтверждает наличие современного оружия у России

Певцы для Ваших Песен.

Новинка от «Турбозавров». Рюкзачки для малышей с героями мультсериала в продаже на Wildberries и Оzon

Сатановский: Россия сделала открытие об американской ПВО благодаря китайскому зонду

Более 800 раз обратились в колл-центр Стройкомплекса по теме изменений в правилах землепользования

«С Казахстаном немножко все сложнее». Почему «Барыс» не попадает в плей-офф и останется ли он в КХЛ

Рыбинец победил во всероссийском турнире по четырехборью

Путин в России и мире

Персональные новости

Любовь Успенская

Дочь Любови Успенской пришла на «Золотой Граммофон» с собакой и вейпом

News Every Day

AMSTERDAM Walking tour and city highlights in 4K

Friends of Today24

Музыкальные новости

Персональные новости